

DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re Application of Dreyer
Customer No.: 051957
Serial No: 10/734,930

Filed: Dec, 12, 2003

For: CALCIUM BLOCKERS TO
TREAT PROLIFERATIVE
VITREORETINOPATHY

Group Art Unit: 1614

Examiner: Fay, Zohreh A.

Confirmation No.: 2241

INFORMATION DISCLOSURE STATEMENT

Attn: Information Disclosure Statement
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled **CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY**, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.


Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date:

3/2/06



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249


I hereby certify that this Information Disclosure Statement and additional documents enclosed herein are being deposited with the United States Postal Service on 3/2/06 in an envelope as "First Class Mail Post Office To Addressee" with sufficient postage for First Class Mail addressed to Attn: Information Disclosure Statement, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date:

3/2/06

BONNIE FERGUSON
Name of person mailing paper

Bonnie Ferguson
Signature of person mailing paper



LIST OF ARTS CITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP (AP)	SERIAL NO.: 10/734,930
APPLICANTS: Evan B. Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIVERATIVE VITREORETINOPATHY
FILING DATE: Dec. 12, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
DA	5,527,810	6/18/1996	Ornstein			

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
					Yes

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

DB	Constable I: "Biological and Therapeutic Aspects of Proliferative Vitreoretinopathy" Japanese Journal of Ophthalmology, Vol. 31, No. 4, 1987, pgs. 513-520, XP008054876
DC	Uchida N. et al: "Glutamate Stimulates Proliferation of Retinal Pigment Epithelium and Its BFGF Expression Through NMDA Receptor Activation", Vol. 71, No. Suppl. 1, 20 March 1996, page 274P, XP008040806
DD	Murphy T L et al: "Migration of retinal pigment epithelium cells in vitro is regulated by protein kinase C", Experimental Eye Research, Vol. 60, No. 6, June 1995, pages 683-695, XP-002102540
DE	Uchida N. et al: "Gltamate-Stimulated Proliferation of Rat Retinal Pigment Epithelium: Through NMDA Receptor Activation and BFGF Expression", Investigative Ophthalmology & Visual Science, Vol. 37, No. 3, 21 April 1996, pages S388, XP008040803
DF	Sakamoto T et al: "Vitamin E Succinate Inhibits Proliferation and Migration of Retinal Pigment Epithelial Cells in Vitro-Therapeutic Implication for Proliferative Vitreoretinopathy", Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 234, No. 3, March 1996, XP008040829
DG	Hackett S. et al: Cyclic 3',5'-Adenosine Monophosphate Modulates Retinal Pigment Epithelial Cell Migration in Vitro", Vol. 104, No. 11, Nov. 1986, pgs. 1688-1692, XP008054877
DF	Hackett S. et al: "Implication of Protein Carboxymethylation in Retinal Pigment Epithelial Cell Chemotaxis", Ophthalmic Research, Vol. 20, No. 1, 1988, pages 54-59
DG	Wagner M. et al: "Effects of Pharmacological Modulation of Intracellular Signalling Systems on Retinal Pigment Epithelial Cell Attachment to Extracellular Matrix Protein", Current Eye Research, Vol. 14, No. 5, May 1995, pages 373-384

EXAMINER _____ **DATE CONSIDERED** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ARTICLES CITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP (AP)	SERIAL NO.: 10/734,930
APPLICANTS: Evan B. Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY
FILING DATE: Dec. 12, 2003	GROUP: 1614

	DH	Kalloniatis M.: "Amino Acids in Neurotransmission and Disease", Journal of the American Optometric Assoc., Vol. 66, No. 12, Dec. 1995, pgs. 750-757, XP008053708
	DI	Solberg Y et al: "Treatment of Laser-Induced Retinal Injuries by Neuroprotection", SPIE, Vol. 2974, 1997, pgs. 158-165
	DJ	Ishikawa S. et al: "Alteration of Glutamine Concentration in the Vitreous Humor in Patients with Proliferative Vitreoretinopathy", Current Eye Research, Vol. 14, No. 3, March 1995, pgs. 191-197, XP008053697
	DK	Haberecht M. et al: "N-Methyl-D-Aspartate-Mediated Glutamate Toxicity in the Developing Rabbit Retina" Journal of Neuroscience Research, Vol. 47, No. 4, 15 Feb. 1997, pgs. 416-426, XP008040828
	DL	Uchida et al: "Glutamate-Stimulated Proliferation of Rat Retinal Pigment Epithelial Cells", European Journal of Pharmacology, Vol. 343, No. 2/3, 19 Feb. 1998, pgs. 265-273, XP008040812

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.